---
slug: retatrutide-glp1-agonists
title: "retatrutide glp1 agonists"
kind: standard
status: published
hash: 3ecbb35fa719d711e036669b9887d02c985648c3ddea9a7f9921743cdc1f9356
created: 2026-06-29T17:43:32.319Z
updated: 2026-10-08T11:49:31.891Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# retatrutide glp1 agonists

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:43:51.697Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide ...](https://pubmed.ncbi.nlm.nih.gov/41723268/) — “Our findings demonstrate that all three GLP-1 analogs, semaglutide, tirzepatide, and retatrutide , exhibit significant anti-obesity effects in MC4R KO mice.” (sha256 4445cb67296f9791)
2. [Efficacy and Safety of GLP-1 Receptor Agonists, Dual ...](https://pubmed.ncbi.nlm.nih.gov/40685589/) — “Retatrutide offers superior weight loss efficacy but with a higher AE risk. Dual agonists provide a favorable efficacy-safety balance.” (sha256 bdda6c0cc48f48ac)
3. [Efficacy and safety of retatrutide, a novel GLP-1, GIP, and ...](https://pubmed.ncbi.nlm.nih.gov/40291085/) — “Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.” (sha256 9626f94ca6280fc9)
4. [Retatrutide-A Game Changer in Obesity Pharmacotherapy](https://pubmed.ncbi.nlm.nih.gov/40563436/) — “Retatrutide's unique molecular structure enables potent activation of GLP - 1 , GIP, and glucagon receptors, leading to significant weight reduction, improved ...” (sha256 ea5d1195a7e17619)
5. [A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)](https://clinicaltrials.gov/study/NCT05882045) — “The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD).” (sha256 710e155420c839f7)
6. [Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes... (TRANSCEND-T2D-1)](https://pubmed.ncbi.nlm.nih.gov/42250575/) — “Retatrutide showed significant ... Two deaths occurred during the study , both in the retatrutide 4 mg group and unrelated to the study drug.” (sha256 15565542487d294b)
7. [Retatrutide in type 2 diabetes mellitus and obesity: an overview](https://pubmed.ncbi.nlm.nih.gov/41785010/) — “Retatrutide (LY3437943) is a novel triple agonist targeting glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1 R).” (sha256 2925e1c548e478ba)
8. [Retatrutide and the Paradigm Shift in Multi-Hormonal ...](https://pubmed.ncbi.nlm.nih.gov/41545327/) — “Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent represents a transformative advance in obesity pharmacotherapy.” (sha256 201f72b0c9789835)
9. [Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/42135195/) — “retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D.” (sha256 4b80eb58b052d9d9)
10. [Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review](https://pubmed.ncbi.nlm.nih.gov/42108533/) — “Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.” (sha256 ac66fd9f6fd80119)
11. [Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models](https://pubmed.ncbi.nlm.nih.gov/41741376/) — “Retatrutide markedly reduced the HOMA-IR index of insulin resistance , hepatic steatosis score, fatty acids, triglycerides, and total cholesterol content.” (sha256 b9440ea6da449ffb)
12. [A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)](https://clinicaltrials.gov/study/NCT07232719) — “The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.” (sha256 be6e6d2a4ec6b8a4)
13. [A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)](https://clinicaltrials.gov/study/NCT06662383) — “The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity.” (sha256 510618aca961ab8d)